Eledon Pharmaceuticals, Inc. (ELDN) stock
Close on Nov 11, 2026Market cap $216.97MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $216.97M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.57
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$98.56M
- EPS, diluted
- -$0.91
- Book value per share
- $0.29
- Diluted shares
- 114M
Trading
- Next earnings
- Nov 13, 2026 (estimated, during market hours)
- Previous close
- $2.76
- Open
- $2.76
- Day's range
- $2.63 – $2.82
- Volume
- 530,934
- Average volume (20 days)
- 897,130
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 0.90
- 52-week range
- $1.35 – $4.49
- RSI (14 days)
- 52.3
- Volatility (1 year)
- 68.9%
- Relative volume
- 0.56×
- WACC
- 9.4%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ELDN | S&P 500 | Difference | ELDN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.7% | -2.4% | +10.1 pts | ||
| 3 months | -28.8% | -1.2% | −27.6 pts | ||
| Year to date | +76.8% | +12.3% | +64.5 pts | ||
| 1 year | +25.4% | +12.4% | +12.9 pts | ||
| 3 years | +130.2% | +78.8% | +51.4 pts | +32.0% | +21.4% |
| 5 years | -46.1% | +75.2% | −121.2 pts | -11.6% | +11.9% |
| 10 years | -98.5% | +311.1% | −409.6 pts | -34.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Eledon Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial ResultsResults
- Results
- Results
About Eledon Pharmaceuticals
Pharmaceutical Preparations
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company that develops immunomodulatory therapies targeting the CD40 Ligand pathway. Its primary investigational product candidate is tegoprubart, an antibody designed to block CD40L signaling to suppress immune responses and promote immune tolerance without causing lymphocyte depletion or platelet activation. The company focuses on developing treatments to prevent organ rejection in both human-to-human allograft and animal-to-human xenograft transplantation, especially kidney transplants, as well as therapies for amyotrophic lateral sclerosis. As a clinical-stage development company without approved commercial products, its end users are intended to be transplant recipients and individuals with neurodegenerative conditions.
Company profile, executives and historyEledon Pharmaceuticals stock: common questions
What is Eledon Pharmaceuticals's stock price?
ELDN closed at $2.67 on Nov 11, 2026, down 3.26% on the day. Over the past 52 weeks it traded between $1.35 and $4.49.
What is Eledon Pharmaceuticals's market cap?
Eledon Pharmaceuticals was worth $216.97M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ELDN's P/E ratio?
Eledon Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.91), so it has no meaningful P/E ratio.
Does Eledon Pharmaceuticals pay a dividend?
No. Eledon Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Eledon Pharmaceuticals report earnings next?
Eledon Pharmaceuticals is expected to report Q3 FY2026 results on Nov 13, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ELDN stock performed over the past year?
Including dividends, ELDN returned +25.4% over the past year, against +12.4% for the S&P 500.
How many ELDN shares are sold short?
8M shares were sold short at the latest FINRA report, 10.23% of the float, or 7.5 days of average trading volume.
Who are Eledon Pharmaceuticals's competitors?
Companies most similar to Eledon Pharmaceuticals by business, industry and size include COYA, REVB, QTTB, VERA, TLSA.
See a number that looks wrong?